Drugs for Contact Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 108)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Triamcinolone |
Approved, Vet_approved |
Phase 4 |
|
124-94-7 |
31307 |
Synonyms:
11b,16a,17a,21-Tetrahydroxy-9a-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
11Β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
9a-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-11b,16a,17a,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-16a-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-16α-hydroxyprednisolone
Adcortyl
Aristocort
ARISTOCORT A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
Celeste
Cinolone
Cinolone-T
DELPHICORT
Fluoxiprednisolone
fluoxiprednisolone|Kenalog®|Nasacort®
Fluoxyprednisolone
Flutex
Fougera
Kenacort
Kenacort-A
Kenacort-Ag
KENALOG
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
Ledercort
|
NASACORT
Nasacort Aq
Nasacort Hfa
NSC-13397
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Rodinolone
Sk-Triamcinolone
TIAMCINOLONUM
Tiamcinolonum [INN-Latin]
Triacet
Triacort
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
TRIAMCINOLONE
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triam-Tablinen
Triatex
Tricortale
Triderm
Trilone
Tri-Nasal
Tristoject
Trymex
Vetalog
Volon
Volon A
|
|
2 |
|
Clobetasol |
Approved, Experimental, Investigational |
Phase 4 |
|
25122-46-7, 25122-41-2 |
2791 5311051 32798 |
Synonyms:
(11b,16b)-21-Chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
(11beta,16beta)-21-Chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
(11Β,16β)-21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
14-(2-Chloroacetyl)-1-fluoro-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl propanoic acid
21-CHLORO-9-FLUORO-11BETA,17-DIHYDROXY-16BETA-METHYLPREGNA-1,4-DIENE-3,20-DIONE 17-PROPIONATE
21-CHLORO-9-FLUORO-11Î’,17-DIHYDROXY-16Î’-METHYLPREGNA-1,4-DIENE-3,20-DIONE 17-PROPIONATE
CCI-4725
CCI-4725|Clobex®|Dermovate®|GR 2/925|Temovate®
CLARELUX
CLOBADERM
Clobecort amex
CLOBETASOL
Clobetasol 17 propionate
CLOBETASOL 17-PROPANOATE
Clobetasol 17-propionate
Clobetasol propionate
CLOBETASOL PROPIONATE (EMOLLIENT)
|
CLOBETASOL PROPIONATE E
Clobetasol propionic acid
Clobetasolum
Clobex
Clofenazon
Cormax
Dermovate
DERMOVATE NN
Embeline
Embeline e
ETRIVEX
GR 2/925
IMPOYZ
OLUX
OLUX E
Temovate
TEMOVATE E
|
|
3 |
|
Glycerin |
Approved, Investigational |
Phase 4 |
|
56-81-5 |
753 |
Synonyms:
(2,5-Dihydroxyphenyl)-acetate
(2,5-Dihydroxyphenyl)-acetic acid
(2E)-2-Butenedioate
(2E)-2-Butenedioic acid
(2E)-But-2-enedioate
(2E)-But-2-enedioic acid
(e)-2-Butenedioate
(e)-2-Butenedioic acid
1,2,3-Propanetriol
1,2,3-Trihydroxypropane
2-(3,6-DIHYDROXYPHENYL)acetate
2-(3,6-DIHYDROXYPHENYL)acetIC ACID
2-(e)-Butenedioate
2-(e)-Butenedioic acid
2,5-Dihydroxy-alpha-toluate
2,5-Dihydroxy-alpha-toluic acid
2,5-Dihydroxy-a-toluate
2,5-Dihydroxy-a-toluic acid
2,5-Dihydroxy-benzeneacetate
2,5-Dihydroxy-benzeneacetic acid
2,5-Dihydroxyphenylacetate
2,5-Dihydroxyphenylacetic acid
Acid, homogentisic
Alcapton
Allomaleate
Allomaleic acid
alpha-delta-Glucopyranuronic acid
alpha-delta-Glucuronic acid
alpha-D-Glucopyranuronic acid
alpha-D-Glucuronic acid
Ammonium fumarate
Boletate
Boletic acid
Bulbold
Concentrated glycerin
Cristal
D-(+)-Glucuronate
D-(+)-Glucuronic acid
delta-(+)-Glucuronate
delta-(+)-Glucuronic acid
delta-Glucuronate
D-Glucuronate
e 422
e297
Emery 916
FC 33
Fumarate
Fumarsaeure
Furamag
GCU
GlcAa
GlcAalpha
|
Glucosiduronate
Glucosiduronic acid
Glucuronate
Glucuronic acid
Glyceol opthalgan
Glycerin
Glycerin, anhydrous
Glycerin, concentrated
Glycerin,anhydrous
Glycerine
glycérine
Glycerinum
Glyceritol
Glycerol
glycérol
Glycerolum
Glycyl alcohol
Glyrol
Glysanin
Glyzerin
Gro
Homogentisate
Homogentisate acid
Homogentisinate
Homogentisinic acid
IFP
Incorporation factor
Lichenate
Lichenic acid
Mackstat H 66
Mafusol
Magnesium fumarate
Melanic acid
Monoctanoin component D
Oelsuess
Ölsüß
Osmoglyn
Pricerine 9091
Propanetriol
RG-S
Sodium fumarate
trans-1,2-Ethylenedicarboxylate
trans-1,2-Ethylenedicarboxylic acid
trans-2-Butenedioate
trans-2-Butenedioic acid
trans-But-2-enedioate
trans-But-2-enedioic acid
trans-Butenedioate
trans-Butenedioic acid
Trihydroxypropane
Tryhydroxypropane
|
|
4 |
|
Mineral oil |
Approved, Vet_approved |
Phase 4 |
|
8042-47-5 |
|
Synonyms:
Food Grade Mineral Oil
Heavy Liquid Petrolatum
Heavy mineral oil
Liquid Paraffin
Liquid Petrolatum
Mineral oil
Mineral Oil (high Viscosity)
|
Mineral Oil, Heavy
Paraffin Oil
Paraffin, Liquid
Paraffinum Liquidum
Petrolatum, Liquid
White Mineral Oil
|
|
5 |
|
Povidone K30 |
Approved, Experimental, Withdrawn |
Phase 4 |
|
9003-39-8 |
6917 131751496 |
Synonyms:
1-Ethenyl-2-pyrrolidinone
1-Ethenyl-2-pyrrolidinone (9ci)
1-Ethenyl-2-pyrrolidinone homopolymer
1-Ethenyl-2-pyrrolidinone homopolymer, 9ci
1-Ethenyl-2-pyrrolidinone polymers
1-Ethenyl-2-pyrrolidinone, homopolymer
1-Vinyl-2-pyrrolidinone
1-Vinyl-2-pyrrolidinone cross-linked insoluble polymer
1-Vinyl-2-pyrrolidinone homopolymer
1-Vinyl-2-pyrrolidinone polymer
1-Vinyl-2-pyrrolidinone, monomer
1-Vinyl-2-pyrrolidinone, polymer
1-Vinyl-2-pyrrolidone
1-Vinyl-2-pyrrolidone polymer
1-Vinylpyrrolidin-2-one
1-vinylpyrrolidin-2-one homopolymer
1-Vinylpyrrolidinone
1-Vinylpyrrolidone
2-Pyrrolidinone, 1-ethenyl, homopolymer
2-Pyrrolidinone, 1-ethenyl-, homopolymer
2-Pyrrolidinone, 1-vinyl-, polymers
Agent at 717
Agent at-717
Agrimer
Albigen a
Aldacol Q
Alphadine
Alphadines
Antaron P 804
Arufil
Betadine
Betadines
Betaisodona
Betaisodonas
Bolinan
Bolinan 40
Crospovidone
Disadine
Disadines
Dulcilarme
Dulcilarmes
Duratears free
Enterode
Enterodes
Enterodez
Ganex P 804
Ganex P-804
Hemodesis
Hemodez
Huntington laboratories brand OF povidone iodine
Huntington laboratories brand OF povidone-iodine
Hypotear
Hypotears
Isodine
Isodines
K 115 (Polyamide)
K 25
K 25 (Polymer)
K 30
K 30 (Polymer)
K 60
K 60 (Polymer)
K115 (Polyamide)
K25 (Polymer)
K30 (Polymer)
K60 (Polymer)
Kollidin CLM
Kollidon
Kollidon 17
Kollidon 25
'Kollidon 25'
Kollidon 30
Kollidon CL
Lacophtal
Lacri-stulln
Lagrifilm
Liquifilm lagrimas
Luviskol
Luviskol K 30
Luviskol K 90
Luviskol K30
Luviskol K-30
Luviskol K90
N- Vinyl pyrrolidone
Neocompensan
Nutrivisc
N-Vinyl pyrrolidone
N-Vinyl-2-pyrrolidinone
N-Vinyl-2-pyrrolidone
N-Vinyl-2-pyrrolidone polymer
N-Vinylbutyrolactam polymer
N-Vinylpyrrolidinone
N-Vinylpyrrolidinone polymer
N-Vinylpyrrolidone
N-Vinylpyrrolidone polymer
N-Vinylpyrrolidone-2
Oculotect
Peragal ST
Peregal ST
Periston
Periston-N
Peviston
Pharmadine
Pharmadines
'plasdone'
Plasdone
Plasdone 4
Plasdone K 29-32
Plasdone K-26/28
Plasdone K29/32
Plasdone K29-32
|
Plasdone no. 4
Plasdone XL
Plasmosan
Polividone
Polvidone
Poly(1-(2-oxo-1-pyrrolidinyl)-1,2-ethanediyl)
Poly(1-(2-oxo-1-pyrrolidinyl)ethylene)
Poly(1-ethenyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone) homopolymer
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.1
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.2
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.3
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.4
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.5
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.6
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.7
Poly(1-vinyl-2-pyrrolidone)
Poly(1-vinylpyrrolidinone)
Poly(N-vinyl-2-pyrrolidinone)
Poly(N-vinyl-2-pyrrolidone)
Poly(N-vinylbutyrolactam)
Poly(N-vinylpyrrolidinone)
Poly(N-vinylpyrrolidone)
Poly(vinylpolypyrrolidone)
Poly(vinylpyrrolidinone)
Poly(vinylpyrrolidone)
Polyclar a. t
Polyclar a. t.
Polyclar at
Polyclar H
Polyclar L
Polyclar-at
Polygyl
Poly-N-vinyl pyrrolidone
Poly-N-vinylpyrrolidone
Polyplasdone
Polyplasdone XL
Polyvidon
Polyvidons
Polyvidonum
Polyvinyl pyrrolidone
Polyvinylpolypyrrolidone
Polyvinylpyrrolidone
Polyvinylpyrrolidone iodine
Polyvinylpyrrolidone iodines
Polyvinylpyrrolidone K 30
Polyvinylpyrrolidone K-29/32
Polyvinylpyrrolidone K30
Polyvinylpyrrolidone polymers
Polyvinylpyrrolidone, cross-linked
Povidona
Povidone
Povidone iodine
Povidone K29/32
Povidone K29-32
Povidone(usan)
Povidone, ban, usan
Povidone, unspecified
Povidone-iodine
Povidone-iodines
Povidonum
Protagen
Protagens
Protagent
Providine
Providines
PVP 1
PVP 2
PVP 3
PVP 4
PVP 40
PVP 5
PVP 6
PVP 7
PVP Iodine
PVP K 3
PVP K30
PVP K-30
PVP10_SIAL
PVP40_SIAL
PVP-I
PVP-Iodine
PVP-Iodines
PVP-K 15
PVP-K 3
PVP-K 30
PVP-K 60
PVP-K 90
PVPP
Refresh
Sauflon
Soothe
Subtosan
Tears plus
Tolpovidone I 131
Tolpovidone I-131
Toxobin
Unifluid
Unspecified povidone
Vidirakt S mit PVP
Vidisic PVP ophtiole
Vinisil
Vinyl-2-pyrrolidone
Vinylbutyrolactam
Vinylpyrrolidinone
Vinylpyrrolidinone polymer
Vinylpyrrolidone
Vinylpyrrolidone polymer
V-Pyrol
Wet-comod
|
|
6 |
|
Tacrolimus |
Approved, Investigational |
Phase 4 |
|
104987-11-3 |
6473866 445643 |
Synonyms:
(-)-FK 506
Anhydrous tacrolimus
Anhydrous, tacrolimus
Cilag brand OF tacrolimus
FK5
FK506
FK-506
FK506|fujimycin|Prograf®|Protopic®
FR-900506
FUJIMYCIN
Fujisawa brand OF tacrolimus
Janssen brand OF tacrolimus
|
K506
LCP-Tacro
Prograf
Prograft
PROTOPIC
Tacarolimus
TACROLIMUS
Tacrolimus anhydrous
tacrolimus hydrate
TACROLIMUS MONOHYDRATE
Tacrolimus, anhydrous
|
|
7 |
|
Triamcinolone hexacetonide |
|
Phase 4 |
|
|
|
Synonyms:
ARISTOSPAN
CL-34433
LEDERSPAN
|
TATBA
TRIAMCINOLONE HEXACETONIDE
|
|
8 |
|
Triamcinolone diacetate |
|
Phase 4 |
|
|
|
Synonyms:
ARISTOCORT
KENACORT
ORION
POLCORTOLON
|
TEDAROL
TRIAMCINOLONE 16,21-DIACETATE
TRIAMCINOLONE DIACETATE
|
|
9 |
|
Triamcinolone Acetonide |
|
Phase 4 |
|
|
6436 |
Synonyms:
ADCORTYL
ADCORTYL IN ORABASE
ALLERNAZE
ARISTOCORT
ARISTOCORT A
ARISTOGEL
AUDICORT
AUREOCORT
AZMACORT
FLUTEX
GPPE EAR DPS CAP
GPPE EAR OINT
KENACORT
KENACOURT
KENALOG
KENALOG IN ORABASE
KENALOG-10
KENALOG-40
KENALOG-80
KENALOG-H
NASACORT
NASACORT ALLERGY 24 HOUR
NASACORT AQ
|
NASACORT HFA
NSC-21916
NYSTADERMAL
ORACORT
ORALONE
PEVARYL T.C.
REMIDERM
REMOTIC
SILDERM
TRIACET
TRIACORT
TRI-ADCORTYL
TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE
TRIATEX
TRIDERM
TRIESENCE
TRI-NASAL
TRIVARIS
TRYMEX
VETALOG
ZILRETTA
Zilretta®
|
|
10 |
|
Emollients |
|
Phase 4 |
|
|
|
11 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
12 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
13 |
|
Calcineurin Inhibitors |
|
Phase 4 |
|
|
|
14 |
|
Afamelanotide |
Approved, Investigational |
Phase 3 |
|
75921-69-6 |
16132954 16197727 |
Synonyms:
α-NDP-MSH|[Nle4,dPhe7]α-MSH|CUV-1647|CUV1647|NDP-MSH|Scenesse®
4-({1-[(1-{[1-({1-[({[6-amino-1-(2-{[1-(C-hydroxycarbonimidoyl)-2-methylpropyl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl)-1-oxohexan-2-yl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-(1H-indol-3-yl)ethyl}-C-hydroxycarbonimidoyl)-4-carbamimidamidobutyl]-C-hydroxycarbonimidoyl}-2-phenylethyl)-C-hydroxycarbonimidoyl]-2-(1H-imidazol-5-yl)ethyl}-C-hydroxycarbonimidoyl)-4-({2-[(2-{[2-({1,3-dihydroxy-2-[(1-hydroxyethylidene)amino]propylidene}amino)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyhexylidene}amino)butanoate
AFAMELANOTIDE
CUV1647
CUV-1647
|
Melanotan 1
Melanotan I
Melanotan-1
MT-I
SCENESSE
|
|
15 |
|
Petrolatum |
Approved, Investigational |
Phase 2, Phase 3 |
|
8009-03-8 |
|
Synonyms:
Multi-hydrocarbon
Paraffinum album
Paraffinum flavum
Petrolatum
Petrolatum base
Petrolatum, white
Petrolatum,amber
|
Petrolatum,white
Petroleum jelly
Soft paraffin
White petrolatum
White, soft paraffin
Yellow soft paraffin
|
|
16 |
|
Fluticasone |
Approved, Experimental |
Phase 2, Phase 3 |
|
90566-53-3 |
4659387 5311101 |
Synonyms:
ADVAIR
Advair®|Avamys®|Flovent HFA®|Veramyst®
FLOVENT HFA
Fluticason
|
Fluticasona
Fluticasone
Fluticasonum
VERAMYST
|
|
17 |
|
Betamethasone |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
378-44-9 |
9782 |
Synonyms:
16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione
16b-Methyl-1,4-pregnadiene-9a-fluoro-11b,17a,21-triol-3,20-dione
16Β-methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione
9a-Fluoro-16b-methylprednisolone
9alpha-Fluoro-16beta-methylprednisolone
9-Fluoro-16beta-methylprednisolone
9-Fluoro-16b-methylprednisolone
9-Fluoro-16β-methylprednisolone
9Α-fluoro-16β-methylprednisolone
ALPHATREX
BESAMESTAZONA
Betadexamethasone
Betametasona
BETAMETHASONE
Bétaméthasone
beta-Methasone alcohol
Betamethasonum
BETAMETHASONVALERAT MIKRON
BETASOLAN
|
BETATREX
BETA-VAL
BETNELAN
b-Methasone alcohol
Celeston
Celestona
Celestone
Cellestoderm
DERMABET
Flubenisolone
LOTRISONE
NSC-39470
Rinderon
SCH-4831
TACLONEX
UTICORT
VISUBETA
Î’-methasone alcohol
|
|
18 |
|
Adalimumab |
Approved, Experimental |
Phase 2, Phase 3 |
|
331731-18-1 |
|
Synonyms:
ADALIMUMAB
ADALIMUMAB (GENETICAL RECOMBINATION)
ADALIMUMAB BETA
adalimumab-adaz
adalimumab-adbm
adalimumab-afzb
adalimumab-atto
adalimumab-bwwd
adalimumab-fkjp
AVT-02
BI695501
CT-P17
D2E7
FKB327
|
FKB-327
GP2017
HLX03
HLX-03
HUMIRA
Humira Pen
IG GAMMA-1 CHAIN C REGION
LU200134
LU-200134
M923
MSB11022
MSB-11022
ZRC3197
ZRC-3197
|
|
19 |
|
Ustekinumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
815610-63-0 |
|
Synonyms:
CNTO-1275
STELARA
STELERA
|
|
|
20 |
|
Coconut |
Approved |
Phase 3 |
|
|
|
21 |
|
Cholecalciferol |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
67-97-0, 1406-16-2 |
5280795 10883523 |
Synonyms:
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,4E,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3BETA,Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
(3Î’,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
3-BETA,Z,7E-9,10-SECOCHOLESTR-5,7,10(19)-TRIEN-3-OL
7-DEHYDROCHOLESTEROL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
ACCRETE D3
ACIFEROL D3
ACTIVATED
Activated 7-dehydrocholesterol
ADCAL-D3
ARACHITOL
AVITICOL
BIOLIFE VITAMIN D3
BIO-VITAMIN D3
CACIT D3
CALCEOS
CALCICHEW D3
CALCICHEW D3 FTE
CALCICHEW D3 ONCE DAILY
CALCI-D
Calciferol
Calciol
CALDRINK D3
CALFOVIT D3
CC
Cholecalciferol
CHOLECALCIFEROL D3
Cholecalciferols
Cholecalciferolum
COLECAL D3
Colecalciferol
Colecalciferolum
COLEKAL-D3
COLEVIT D3
CUBICOLE D3
D3 LEMON MELTS
D3-50
D3-VIGANTOL
DEKRISTOL
DELSTEROL
Delta-D
DEPARAL
DESUNIN
DEVARON
Dihydrocholesterol
DLUX 400
D-MAX
D-TRACETTEN
|
D-VIT3
EBIVIT
E-D3
EVACAL D3
FERACOL
FULTIUM DAILY D3
FULTIUM-D3
GRANUVIT D3
HUX D3
INVITA D3
ISO D3
KORA LIQUID
MICRO-DEE
NATECAL D3
NATURE'S REMEDY VITAMIN D3
NEO-D
NPHD3
NSC-375571
Oleovitamin D3
OSTEOCAPS D3
PLENACHOL
PRO D3
PRO D3 FOLIC
PRO D3 FORTE
PROVITINA
QUINTOX
RICKETON
ROYALVIT D3
STEXEROL-D3
STIVIT-D3
SUNVIT-D3 1,000
SUNVIT-D3 10,000
SUNVIT-D3 2,000
SUNVIT-D3 20,000
SUNVIT-D3 3,000
SUNVIT-D3 400
SUNVIT-D3 5,000
SUNVIT-D3 50,000
SUNVIT-D3 800
SYNERVIT-D3
THEICAL D-3
THORENS
TRIVITAN
VIDDE-3-HYDROSOL
VI-DE3
VIDEKHOL
VIGANTOL
VIGANTOLETTEN
VIGANTOLETTEN 500
VIGORSAN
VIT D3 STREULI
VITA-D3
VITAMIN D
Vitamin D 3
VITAMIN D ASSAY SYSTEM SUITABILITY
Vitamin D NOS
Vitamin D, unspecified form
Vitamin D3
Vitamin D-3
VITINC DAN-DEE-3
ZYMAD
δ-D
|
|
22 |
|
Squaric acid dibutyl ester |
Investigational |
Phase 2, Phase 3 |
|
2892-62-8 |
|
Synonyms:
Squaric acid dibutyl ester
|
Squaric acid dibutylester
|
|
23 |
|
Bronchodilator Agents |
|
Phase 2, Phase 3 |
|
|
|
24 |
|
Anti-Asthmatic Agents |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
Adjuvants, Immunologic |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
Betamethasone-17,21-dipropionate |
|
Phase 2, Phase 3 |
|
|
|
27 |
|
Betamethasone Valerate |
|
Phase 2, Phase 3 |
|
2152-44-5 |
|
Synonyms:
AUDAVATE
AUDAVATE RD
BETACAP
BETADERM
BETAMETH VAL 0.1% 50% IN EMULSIF
BETAMETH VAL IN COAL TAR
BETAMETH VAL OINT 0.1% 25%COAL TAR
BETAMETH VAL OINT 0.1% 50% COALTAR
BETAMETH VAL OINT0.025% 50%COALTAR
BETAMETHASONE 17-VALERATE
BETAMETHASONE VALERATE
BETATREX
BETA-VAL
|
BETESIL
BETNOVATE RD
BETNOVATE-C
BETNOVATE-N
BETTAMOUSSE
BEXTASOL
DERMABET
FUCIBET
LUXIQ
VALISONE
VALNAC
XEMACORT
|
|
28 |
|
Betamethasone sodium phosphate |
|
Phase 2, Phase 3 |
|
|
|
Synonyms:
BETAMETHASONE 21-PHOSPHATE DISODIUM SALT
BETAMETHASONE SODIUM PHOSPHATE
BETAM-OPHTAL
BETNESOL
BETNESOL-N
|
CELESTONE
NSC-90616
VISTAMETHASONE
VISTAMETHASONE N
|
|
29 |
|
Betamethasone benzoate |
|
Phase 2, Phase 3 |
|
|
|
Synonyms:
BETAMETHASONE BENZOATE
UTICORT
|
|
|
30 |
|
Anti-Allergic Agents |
|
Phase 2, Phase 3 |
|
|
|
31 |
|
Xhance |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Anesthetics, Local |
|
Phase 2, Phase 3 |
|
|
|
33 |
|
Anesthetics |
|
Phase 2, Phase 3 |
|
|
|
34 |
|
Respiratory System Agents |
|
Phase 2, Phase 3 |
|
|
|
35 |
|
Analgesics |
|
Phase 2, Phase 3 |
|
|
|
36 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
37 |
|
Interleukin 1 Receptor Antagonist Protein |
|
Phase 3 |
|
|
|
38 |
|
Hormones |
|
Phase 3 |
|
|
|
39 |
|
Trace Elements |
|
Phase 3 |
|
|
|
40 |
|
Micronutrients |
|
Phase 3 |
|
|
|
41 |
|
Vitamins |
|
Phase 3 |
|
|
|
42 |
|
Calciferol |
|
Phase 3 |
|
|
|
43 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
44 |
|
Calcium |
Nutraceutical |
Phase 3 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
45 |
|
Apremilast |
Approved, Investigational |
Phase 2 |
|
608141-41-9 |
10151715 11561674 |
Synonyms:
APREMILAST
APRÉMILAST
APREMILASTUM
CC 10004
CC10004
|
CC-10004
CC-10004|Otezla®
N-{2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULFONYL)ETHYL]-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL}ACETAMIDE
OTEZLA
|
|
46 |
|
Thalidomide |
Approved, Investigational, Withdrawn |
Phase 2 |
|
50-35-1 |
5426 |
Synonyms:
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(+-)-THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(±)-THALIDOMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
3-PHTHALIMIDOGLUTARIMIDE
Algosediv
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
alpha-Phthalimidoglutarimide
Asidon 3
Asmadion
Asmaval
Bonbrain
Bonbrrin
Calmore
Calmorex
Celgene brand OF thalidomide
Contergan
Corronarobetin
Distaval
Distaxal
Distoval
Ectiluran
Enterosediv
Gastrinide
Glupan
Glutanon
Grippex
Hippuzon
Imida-Lab
Imidan
Imidene
Isomin
K-17
Kedavon
Kevadon
Lulamin
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Neaufatin
Neo
Neosedyn
Neosydyn
Nerosedyn
Neufatin
Neurodyn
Neurosedin
Neurosedym
Neurosedyn
Nevrodyn
Nibrol
Noctosediv
Noxodyn
|
N-Phthalimidoglutamic acid imide
N-Phthaloylglutamimide
N-Phthalylglutamic acid imide
N-PHTHALYL-GLUTAMINSAEURE-IMID
NSC-527179
NSC-66847
Pangul
Pantosediv
Poly-Giron
Polygripan
Predni-Sediv
Pro-ban M
Profarmil
Psycholiquid
Psychotablets
Quetimid
Quietoplex
Sandormin
Sedalis
Sedalis sedi-lab
Sedimide
Sedin
Sedisperil
Sedoval
Shin-naito S
Shinnibrol
Sleepan
Slipro
Softenil
Softenon
Talargan
TALIDEX
TALIDOMIDA
Talimol
Talismol
Telagan
Telargan
Telargean
Tensival
Thaled
Thalidomide
THALIDOMIDUM
Thalidomine usp26
Thalin
Thalinette
Thalomid
Theophilcholine
Valgis
Valgraine
Yodomin
Α-(N-PHTHALIMIDO)GLUTARIMIDE
Α-N-PHTHALYLGLUTARAMIDE
Α-PHTHALIMIDOGLUTARIMIDE
|
|
47 |
|
Mechlorethamine |
Approved, Investigational |
Phase 2 |
|
51-75-2 |
4033 |
Synonyms:
2,2'-Dichloro-N-methyldiethylamine
b,Beta'-dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
BIS (2-CHLOROETHYL) METHYLAMINE
Bis(2-chloroethyl)methylamine
Bis(b-chloroethyl)methylamine
Bis(beta-chloroethyl)methylamine
Bis(β-chloroethyl)methylamine
Caryolysine
Chlorethazine
Chlormethine
Chlormethinum
Cloramin
Clormetina
Embichin
HN2
HN-2
Hydrochloride N-oxide, mechlorethamine
Hydrochloride, mechlorethamine
MBA
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethamine hydrochloride N oxide
Mechlorethamine hydrochloride N-oxide
Mechlorethamine N oxide
Mechlorethamine N-oxide
Mechlorethamine oxide
Mechloroethamine
Mecloretamina
|
Merck brand OF mechlorethamine hydrochloride
Merck frosst brand OF mechlorethamine hydrochloride
Methylbis(2-chloroethyl)amine
Methylbis(b-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methylbis(β-chloroethyl)amine
Methylchlorethamine
Mitomen
Mustargen
Mustine
Nitrogen mustard
Nitrogen mustard N oxide
Nitrogen mustard N-oxide
NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE
Nitrogranulogen
Nitromin
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(b-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis(β-chloroethyl)amine
N-Oxide, mechlorethamine hydrochloride
N-Oxide, nitrogen mustard
NSC 762
NSC-10107
NSC-128663
NSC-762
Î’,beta'-dichlorodiethyl-N-methylamine
β,β'-dichlorodiethyl-N-methylamine
|
|
48 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
49 |
|
Phosphodiesterase Inhibitors |
|
Phase 2 |
|
|
|
50 |
|
Phosphodiesterase 4 Inhibitors |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 81)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 |
Unknown status |
NCT00311454 |
Phase 4 |
T.R.U.E.Test |
2 |
Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation |
Unknown status |
NCT00779792 |
Phase 4 |
clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin) |
3 |
Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations |
Completed |
NCT01798589 |
Phase 4 |
Ethylenediamine dihydrochloride allergen patch |
4 |
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 0.1% Tacrolimus Ointment in the Treatment of Chronic Allergic Contact Dermatitis |
Completed |
NCT00667056 |
Phase 4 |
tacrolimus ointment;placebo ointment |
5 |
Clinical Evaluation of T.R.U.E. TEST® Panel 1.1, 2.1 and 3.1: in Children and Adolescents |
Completed |
NCT00795951 |
Phase 4 |
|
6 |
The Effects of Dupilumab on Allergic Contact Dermatitis |
Recruiting |
NCT03935971 |
Phase 4 |
Dupilumab |
7 |
Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis |
Unknown status |
NCT01011621 |
Phase 3 |
0.5% prednisolone acetate cream;0.1% betamethasone valerate cream |
8 |
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-Butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol |
Completed |
NCT00640614 |
Phase 3 |
|
9 |
A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE) |
Completed |
NCT04704713 |
Phase 3 |
Afamelanotide;Placebo |
10 |
Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction Blistering |
Recruiting |
NCT05535738 |
Phase 2, Phase 3 |
Squaric Acid Dibutyl Ester;Dupilumab;Adalimumab;Ustekinumab;Guselkumab;Canakinumab;Sarilumab;Triamcinolone Acetonide;Betamethasone Valerate;Fluticasone Propionate |
11 |
Comparing Tissue Adhesives in Port Site Closure: A Randomized Controlled Trial |
Recruiting |
NCT05492721 |
Phase 3 |
|
12 |
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis: A Randomized Controlled Trial With Anakinra vs. Placebo |
Not yet recruiting |
NCT05498467 |
Phase 3 |
Anakinra;Sodium Chloride 9mg/ml Injection |
13 |
Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial |
Terminated |
NCT01595893 |
Phase 3 |
Oral Vitamin D 3;Miglyol 812 N |
14 |
Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents |
Withdrawn |
NCT01518348 |
Phase 3 |
|
15 |
Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study |
Completed |
NCT02028208 |
Phase 2 |
|
16 |
Clinical Evaluation of Hydroxyisohexyl 3-cyclohexene Carboxaldehyde (Lyral®) Dose Response Study |
Completed |
NCT02028182 |
Phase 2 |
|
17 |
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study |
Completed |
NCT00640250 |
Phase 2 |
|
18 |
A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm |
Completed |
NCT00867607 |
Phase 1, Phase 2 |
MRX-6;Steroid |
19 |
A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis |
Completed |
NCT00931242 |
Phase 2 |
Apremilast |
20 |
Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study |
Completed |
NCT00132600 |
Phase 2 |
bacitracin (allergen) |
21 |
Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for "TRUE Test® Panel 3" - a Phase II, Dose-Response Study. |
Completed |
NCT00133341 |
Phase 2 |
Goldnatriomthiosulphate, MDBGN, parthenolide |
22 |
Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study) |
Completed |
NCT03380026 |
Phase 2 |
Triamcinolone;Valchlor 0.016 % Topical Gel |
23 |
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis |
Completed |
NCT00928447 |
Phase 2 |
rHuPH20;Placebo |
24 |
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations |
Completed |
NCT00612768 |
Phase 2 |
|
25 |
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects With Chronic Allergic Contact Dermatitis |
Active, not recruiting |
NCT03680131 |
Phase 2 |
EB01 Cream Placebo;EB01 Cream 0.2%;EB01 Cream 1.0%;EB01 Cream 2.0% |
26 |
A Phase I, Single-Center, Double-Blind, Randomized, Single Ascending Dose Study of PDC-APB in Healthy Volunteers |
Completed |
NCT02700373 |
Phase 1 |
PDC-APB;Placebo |
27 |
A Randomized, Controlled Study to Evaluate the Effect of Topically Applied BBI-2000 (5%) on Allergic Responses in Subjects With Contact Hypersensitivity to Diphencyprone |
Completed |
NCT03089775 |
Phase 1 |
BBI-2000;Vehicle |
28 |
Phase 1 Study to Demonstrate Efficacy of Epikeia Coatings in a Human Clinical Trial |
Completed |
NCT00614289 |
Phase 1 |
|
29 |
A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis |
Completed |
NCT01244607 |
Phase 1 |
Placebo;NI-0801 |
30 |
A Single-Site Study To Evaluate the Sensitization Potential of Topically Applied ATx201 in Healthy Human Volunteers |
Completed |
NCT03375957 |
Phase 1 |
ATx201;ATx201 Placebo Gel |
31 |
Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study). |
Completed |
NCT01529320 |
Phase 1 |
Adventan® (methylprednisolone aceponate 0,1%) |
32 |
A Phase I, Single-Center, Double-Blind, Randomized Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB in Healthy Volunteers With a History of Contact Dermatitis Due to Poison Ivy Exposure |
Not yet recruiting |
NCT04853823 |
Phase 1 |
PDC-APB |
33 |
Bariederm Cream in Chronic Contact Dermatitis |
Unknown status |
NCT02026700 |
|
|
34 |
Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation |
Unknown status |
NCT00445029 |
|
|
35 |
Nickel Desensitization Using Topical Therapy |
Unknown status |
NCT01413477 |
|
Calcipotriol, Betamethasone, Calcipotriol & Betamethasone |
36 |
The Use of Coconut Oil for the Prevention and Treatment of Diaper Dermatitis in the NICU Population |
Unknown status |
NCT02614248 |
|
|
37 |
Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects |
Completed |
NCT00929981 |
|
Tablet Methylprednisolone (4 or 16 mg) |
38 |
Low Dose Exposure to Oxidized R-limonene - A Double Blinded Vehicle Controlled Repeated Open Application Test (ROAT) Study |
Completed |
NCT03313232 |
|
|
39 |
Evaluation of the Clinical Implication of Short Repeated Nickel Exposures |
Completed |
NCT03309215 |
|
|
40 |
Exploratory Study of Natural Killer Cells in Human Skin |
Completed |
NCT00824889 |
|
|
41 |
Specific Factors Associated With the Development of Incontinence- Associated Dermatitis (IAD) in ICU Patients Suffering From Fecal Incontinence: Matched Case Control Study |
Completed |
NCT02996357 |
|
|
42 |
An Open Label Study of the Therapeutic Effects of Tetrix Cream in Allergic Contact and Irritant Contact Dermatitis |
Completed |
NCT00646867 |
|
|
43 |
Histopathological Comparison Between Superficial Pressure Ulcers and Incontinence-associated Dermatitis |
Completed |
NCT03685929 |
|
|
44 |
Alteration of the microRNA-126 Expression: a Possible Mechanism in Allergic Contact Dermatitis to Nickel |
Completed |
NCT04365140 |
|
|
45 |
Comparison of the Effectiveness and Safety Between Moisturizing Cream Containing Niacinamide 4% and Virgin Coconut Oil 30% for Secondary Prevention of Occupational Hand Hermatitis in Intensive Care Unit Nurses: a Double Blind Randomized Clinical Trial |
Completed |
NCT04218500 |
|
|
46 |
Oral Human Administration of Red Grape Polyphenol in Nickel-mediated Allergic Contact Dermatitis: an in Vitro Study |
Completed |
NCT03902392 |
|
|
47 |
Epidemiology and Co-Reactivity of Novel Surfactant Allergens |
Completed |
NCT02534441 |
|
|
48 |
Regional Differences of Cutaneous Irritation and Its Effect on Skin Barrier Recovery: A Randomised, Controlled Trial |
Completed |
NCT03231813 |
|
|
49 |
Children With Aluminium Contact Allergy: Cutaneous Exposure Study |
Completed |
NCT04438135 |
|
|
50 |
Molecular and Cellular Characterization of Spongiotic Dermatitis |
Completed |
NCT00371163 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
pramoxine
|
Pramoxine hydrochloride
|
|